Skip to main content

Pasithea Therapeutics Corp.

corporate_fare Company Profile

Pasithea Therapeutics Corp.

KTTA·NASDAQ·Life Sciences·CIK 0001841330

We are a clinical-stage biotechnology company focused on discovering, researching, and developing innovative treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system (CNS) disorders. We are advancing a pipeline of two therapeutic product candidates. Our lead product candidate is PAS-004, a next-generation macrocyclic Mitogen-Activated Protein Kinase ("MEK") inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 ("MEK 1/2") for potential use in treating various RASopathies, including neurofibromatosis type 1 ("NF1"), and a number of MAPK pathway-driven tumors, such as those driven by BRAFv600 mutations and BRAF fusion tumors. It is also being developed for amyotrophic lateral sclerosis ("ALS") and other indications, including ETS2 driven diseases like inflammatory bowel disease ("IBD"), primary sclerosing cholangitis, and ankylosing spondylitis. MEK 1/2 are protein kinases involved in the mitogen-activated protein kinase, or MAPK pathway, which is important in cellular biology and a frequent target for drug discovery. The MAPK pathway drives cell proliferation, differentiation, survival, and other cellular functions, and its abnormal upregulation is critical for tumor formation and progression, fibrosis, and other diseases. MEK inhibitors block the activation of extracellular signal-regulated kinases ("ERK"), which can lead to cell death and inhibition of tumor growth. Existing MEK inhibitors approved by the U.S. Food and Drug Administration (the "FDA") are marketed for certain cancers and symptomatic, inoperable NF1-associated plexiform neurofibromas ("NF1-PN"). For NF1-PN, Koselugo (selumitinib) and Gomekli (mirdametinib) are FDA approved for adult and pediatric NF1-PN patients.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for KTTA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for KTTA spans 4, 10-Q, 8-K, PRE 14A.

Recent high-impact activity:

  • 10% Holder Coastlands Buys $806K of Pasithea Stock Over Three Sessions
  • Pasithea Q3 Loss Widens to $6.6M as R&D Spend Triples; $41.2M Cash Remains
  • PAS-004 Cuts Cutaneous Neurofibroma Size 41% in Phase 1/1b, Two Partial Responses in Plexiform Tumors
  • FDA Clears IND for Pasithea's PAS-004 in Cutaneous Neurofibromas, Opening Second Phase 2 Path
  • Pasithea to Unveil First PAS-004 NF1 Clinical Data at European Conference

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$20.43M
Diluted EPS
-$2.91
Op. Cash Flow
-$15.21M
Operating Income
-$20.86M
Cash & Equivalents
$55.16M
Debt / Equity
0.00×
Shares Outstanding
23.09M sh
Source: 10-K · filed 2026-03-30 · accession 0001213900-26-036434

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 386,722 shares in KTTA as of the October 30, 2026 settlement, a 121.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 38.6% of KTTA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)386,722 shares as of October 30, 2026
Change vs prior period▲ 121.5%
Days to cover1.00 at avg daily volume of 459,545
Daily short volume (FINRA facilities)38.6% of 53,851 shares on November 20, 2026
5-day average short volume66.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$0.465 -2.86% today
52-week range · as of 2026-11-18 $0.281 – $2.06
Market cap
$17.59M
Volume
100.7K (0.1× avg)
3-mo avg 1.3M
Live data · 2026-11-21 20:26 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KTTA - Latest Insights

KTTA
Nov 17, 2026, 8:42 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.4343
Real-time Price: $0.465 info
Change: +$0.0307 (+7%) info
Market Cap: $17.593M info
KTTA
Nov 13, 2026, 5:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.479
Real-time Price: $0.465 info
Change: -$0.014 (-3%) info
Market Cap: $17.593M info
KTTA
Nov 13, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.510
Real-time Price: $0.465 info
Change: -$0.045 (-9%) info
Market Cap: $17.593M info
KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.465 info
Change: +$0.1059 (+29%) info
Market Cap: $17.593M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.465 info
Change: -$0.085 (-15%) info
Market Cap: $17.593M info
KTTA
Sep 09, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5697
Real-time Price: $0.465 info
Change: -$0.1047 (-18%) info
Market Cap: $17.593M info
KTTA
Aug 21, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.490
Real-time Price: $0.465 info
Change: -$0.025 (-5%) info
Market Cap: $17.593M info
KTTA
Jul 29, 2026, 5:15 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4231
Real-time Price: $0.465 info
Change: +$0.0419 (+10%) info
Market Cap: $17.593M info
KTTA
Jun 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.636
Real-time Price: $0.465 info
Change: -$0.171 (-27%) info
Market Cap: $17.593M info
KTTA
Jun 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.590
Real-time Price: $0.465 info
Change: -$0.125 (-21%) info
Market Cap: $17.593M info
KTTA
Jun 02, 2026, 7:02 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.7267
Real-time Price: $0.465 info
Change: -$0.2617 (-36%) info
Market Cap: $17.593M info
KTTA
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.465 info
Change: -$0.335 (-42%) info
Market Cap: $17.593M info
KTTA
May 15, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7839
Real-time Price: $0.465 info
Change: -$0.3189 (-41%) info
Market Cap: $17.593M info
KTTA
May 04, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8466
Real-time Price: $0.465 info
Change: -$0.3816 (-45%) info
Market Cap: $17.593M info
KTTA
Apr 20, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.850
Real-time Price: $0.465 info
Change: -$0.385 (-45%) info
Market Cap: $17.593M info
KTTA
Apr 01, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.7649
Real-time Price: $0.465 info
Change: -$0.2999 (-39%) info
Market Cap: $17.593M info
KTTA
Mar 30, 2026, 5:45 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.715
Real-time Price: $0.465 info
Change: -$0.250 (-35%) info
Market Cap: $17.593M info
KTTA
Feb 20, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.800
Real-time Price: $0.465 info
Change: -$0.335 (-42%) info
Market Cap: $17.593M info
KTTA
Jan 28, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8529
Real-time Price: $0.465 info
Change: -$0.3879 (-45%) info
Market Cap: $17.593M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets